Weight Loss — Patent Landscape
2
Approved drugs
182
Active US patents
49/100
Avg vulnerability
$30.6B
Annual revenue covered
Originators in Weight Loss
Cliff calendar — next 15 years
20
26
8
27
42
31
4
32
21
33
26
34
13
37
23
38
14
39
5
40
6
41
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Ozempic
semaglutide
|
Novo Nordisk | 178 | 44 | $27.4B | 2026-07-17 |
|
Victoza
liraglutide
|
Novo Nordisk | 4 | 54 | $3.2B | 2037-01-09 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8129343 | Ozempic | method of use | 64 | 2031-12-05 |
| 8129343 | Ozempic | method of use | 64 | 2031-12-05 |
| 8129343 | Ozempic | method of use | 64 | 2031-12-05 |
| 9278123 | Ozempic | method of use | 64 | 2031-12-16 |
| 9278123 | Ozempic | method of use | 64 | 2031-12-16 |
| 9278123 | Ozempic | method of use | 64 | 2031-12-16 |
| 9968659 | Victoza | method of use | 62 | 2037-01-09 |
| 9968659 | Victoza | method of use | 62 | 2037-01-09 |
| 9968659 | Victoza | other | 62 | 2037-07-09 |
| 9968659 | Victoza | other | 62 | 2037-07-09 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8129343 | Ozempic | composition of matter | 0 | 2031-12-05 |
| 8129343 | Ozempic | composition of matter | 0 | 2031-12-05 |
| 8129343 | Ozempic | composition of matter | 0 | 2031-12-05 |
| 8129343 | Ozempic | composition of matter | 0 | 2031-12-05 |
| 8129343 | Ozempic | composition of matter | 0 | 2031-12-05 |
| 11382957 | Ozempic | composition of matter | 6 | 2031-12-16 |
| 11382957 | Ozempic | composition of matter | 6 | 2031-12-16 |
| 11382957 | Ozempic | composition of matter | 6 | 2031-12-16 |
| 8129343 | Ozempic | composition of matter | 6 | 2031-12-05 |
| 8129343 | Ozempic | composition of matter | 6 | 2031-12-05 |
Related
- Weight Loss — full disease profile
- AI Patent Landscape Report — type "weight loss" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner